お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
704951

世界の無菌注射剤市場:分子タイプ、医薬品クラス、用途、地域別

Injectable Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 113 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
世界の無菌注射剤市場:分子タイプ、医薬品クラス、用途、地域別
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 113 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の無菌注射剤市場は、2018年から2023年の予測期間を通じて10.5%のCAGRで推移することが予測されています。

当レポートでは、世界の無菌注射剤市場を調査し、市場の概要、分子タイプ・医薬品クラス・用途・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 市場の成長要因
    • バイオテクノロジーに基づく抗がん剤の開発に焦点を当てた研究開発の推進
    • 生物製剤用プレフィルドシリンジの急速な成長
    • アウトソーシングによる注射剤の供給拡大
  • 市場の阻害要因
    • 在庫管理のコストの高さ
    • ハイエンド装置の厳しい規制要件
  • 市場機会
  • 主な課題

第7章 市場区分

  • 分子タイプ別
    • 低分子
    • 高分子
  • 医薬品クラス別
    • 血液因子
    • サイトカイン
    • ペプチドホルモン
    • 免疫グロブリン
    • モノクローナル抗体(mAb)
    • インスリン
    • その他
  • 用途別
    • 腫瘍
    • 神経
    • 心血管疾患
    • 自己免疫疾患
    • 感染症
    • 疼痛
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Amgen
  • Baxter
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi

第10章 市場の将来展望

目次
Product Code: 62819

The injectable drugs market is expected to register a CAGR of nearly 11.1% during the forecast period. With an upsurge in the number of chronic diseases like diabetes and cancer, the need for drug delivery systems has risen substantially in the market.

From the past one era of healthcare, biologics are increasingly becoming the driving forces of the pharmaceutical industry, and prefilled syringes have gained increased acceptance as delivery systems for injectable drugs in the treatment of chronic diseases. Prefilled syringes are mainly sterilized via autoclaving or by ionizing radiation. Their ease of administration and the greater level of safety have increased the competition among the leading companies of injectable drugs.

With the need for more convenient drug-delivery methods, they are becoming the fastest-growing choices for unit dose medication (minimizing dosing error), in order to reduce the drug waste and increase the product life span.

The prefilled syringes have increased utilization across a wide range of therapeutic areas, such as blood stimulants, therapeutic proteins, and vaccines. With the rapid growth of the emerging markets, there is an increasing demand for patient-friendly parenteral delivery systems. Thus, over the forecast period, a wide expansion of prefilled syringes is expected across the world, This is expected to drive the demand for injectable drugs market.

Key Market Trends

Large Molecule has the Highest Share in the Molecule Type Segment

The large molecule is dominating the market due to the steady rise of biologics, orphan drugs, and precision medicines across the biopharmaceutical industry. Furthermore, in 2017, the US FDA drug approval hit a record high, in which biologics and gene therapies played a significant part. With the increasing approval rate of biologics, the demand for injectable drugs is expected to rise significantly.

North America Region Holds the Largest Market Share of Injectable Drugs Market

North America dominates the Injectable Drugs market, owing to rapid developments in healthcare infrastructure, the presence of major players in the region, huge investments made in the research and development, and increased adoption of oncology-related drugs in hospitals to treat different cancers. Furthermore, the expansion of different companies to increase their production capacities is also drive the North American injectable drugs market.

Competitive Landscape

The key players in this market include Pfizer, Inc., Baxter International, Inc., Amgen Inc. among others. Some of the major players in the market have consolidated partnerships for certain products that allow for ease of manufacturing and distribution. Furthermore, the expansion of different companies to increase their production capacities helps in increasing the overall market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising R&D Focus on Development of Biotechnology-Engineered Anti-cancer Drugs
    • 4.2.2 Rapid Growth in the Usage of Pre-filled Syringes for Biologic Products
    • 4.2.3 Increased Outsourcing Activities Across Value Chain Expected to Boost Supply of Injectable Products
  • 4.3 Market Restraints
    • 4.3.1 High Expenses Associated with Inventory Management
    • 4.3.2 Stringent Regulatory Requirement for High-end Machinery
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Molecule Type
    • 5.1.1 Small Molecule
    • 5.1.2 Large Molecule
  • 5.2 By Drug Class
    • 5.2.1 Blood Factors
    • 5.2.2 Cytokines
    • 5.2.3 Peptide Hormone
    • 5.2.4 Immunoglobulin
    • 5.2.5 Monoclonal Antibodies (mAbs)
    • 5.2.6 Insulin
    • 5.2.7 Other Drug Classes
  • 5.3 By Application
    • 5.3.1 Oncology
    • 5.3.2 Neurology
    • 5.3.3 Cardiovascular Diseases
    • 5.3.4 Autoimmune Diseases
    • 5.3.5 Infectious Diseases
    • 5.3.6 Pain
    • 5.3.7 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novo Nordisk A/S
    • 6.1.2 Amgen Inc.
    • 6.1.3 Baxter International Inc.
    • 6.1.4 Gilead Sciences Inc.
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck & Co. Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi S.A.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.